Published in Virology on October 10, 2005
Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol (2008) 1.77
Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol (2008) 1.49
Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J Virol (2006) 1.45
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A (2006) 1.44
A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine (2006) 1.43
Vaccinia virus l1 protein is required for cell entry and membrane fusion. J Virol (2008) 1.39
Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression. J Virol (2006) 1.22
Smallpox vaccines: targets of protective immunity. Immunol Rev (2011) 1.21
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine (2007) 1.21
A conserved poxvirus NlpC/P60 superfamily protein contributes to vaccinia virus virulence in mice but not to replication in cell culture. Virology (2008) 1.10
Vaccinia virus exhibits cell-type-dependent entry characteristics. Virology (2009) 1.09
Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol (2010) 1.07
Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus. Virology (2010) 1.05
Poxvirus cell entry: how many proteins does it take? Viruses (2012) 1.05
Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol (2010) 1.04
Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge. J Virol (2008) 1.01
Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology (2007) 1.00
Antibody responses to vaccinia membrane proteins after smallpox vaccination. J Infect Dis (2007) 0.99
Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans. Virology (2009) 0.99
A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine (2010) 0.98
An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies. Virology (2011) 0.91
Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein. J Virol (2014) 0.89
Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization. Virol J (2009) 0.87
Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. J Virol (2007) 0.86
Development and evaluation of single domain antibodies for vaccinia and the L1 antigen. PLoS One (2014) 0.84
Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement. J Virol (2010) 0.80
Kinetics and intracellular location of intramolecular disulfide bond formation mediated by the cytoplasmic redox system encoded by vaccinia virus. Virology (2009) 0.79
B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals. Virology (2006) 0.78
Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge. Virology (2011) 0.78
The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry. J Virol (2012) 0.77
Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge. Vaccine (2012) 0.76
The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy. J Virol (2013) 0.75
Crystal structure of glycoprotein B from herpes simplex virus 1. Science (2006) 5.57
A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem (2003) 3.70
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology (2003) 3.20
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host Microbe (2007) 2.97
Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J (2005) 2.95
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol (2010) 2.45
Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. Proc Natl Acad Sci U S A (2007) 2.43
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc Natl Acad Sci U S A (2002) 2.19
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Poxvirus multiprotein entry-fusion complex. Proc Natl Acad Sci U S A (2005) 2.09
Glycoprotein D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1. J Virol (2005) 2.07
Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol (2004) 2.06
Herpes virus fusion and entry: a story with many characters. Viruses (2012) 2.05
Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM). J Virol (2002) 2.03
Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol (2006) 1.94
Protein composition of the vaccinia virus mature virion. Virology (2006) 1.93
Specific association of glycoprotein B with lipid rafts during herpes simplex virus entry. J Virol (2003) 1.92
Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB. J Virol (2010) 1.91
The soluble ectodomain of herpes simplex virus gD contains a membrane-proximal pro-fusion domain and suffices to mediate virus entry. Proc Natl Acad Sci U S A (2004) 1.89
Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J Virol (2005) 1.88
Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J Virol (2005) 1.86
Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J Virol (2005) 1.85
HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology (2006) 1.83
Mutational evidence of internal fusion loops in herpes simplex virus glycoprotein B. J Virol (2007) 1.79
Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface. J Virol (2003) 1.78
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol (2007) 1.77
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
Discovery of antivirals against smallpox. Proc Natl Acad Sci U S A (2004) 1.76
The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J Virol (2005) 1.73
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A (2010) 1.72
Bimolecular complementation defines functional regions of Herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. J Virol (2010) 1.70
Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol (2002) 1.69
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr (2005) 1.68
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
Interactions between HIV-1 Gag molecules in solution: an inositol phosphate-mediated switch. J Mol Biol (2006) 1.65
Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops. J Virol (2009) 1.65
Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J Virol (2006) 1.63
Vaccinia virus A28L gene encodes an essential protein component of the virion membrane with intramolecular disulfide bonds formed by the viral cytoplasmic redox pathway. J Virol (2004) 1.62
Conformation of the HIV-1 Gag protein in solution. J Mol Biol (2006) 1.59
Role of the I7 protein in proteolytic processing of vaccinia virus membrane and core components. J Virol (2004) 1.59
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology (2004) 1.58
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions. J Virol (2007) 1.56